Latest ICONIK service enables more informed, data driven decisions regarding patient treatment and safety
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today launched ICONIK Patient Safety, the latest service to leverage its ICONIK technology platform.
Identifying potentially significant clinical issues in real-time, ICONIK Patient Safety offers a systematic way to monitor safety trends in accumulating data, spot potential safety issues and take appropriate corrective and preventative action while the study is on-going. Data can be queried dynamically at any level of detail (single patient, single site, across an entire study or entire compound), helping sponsors make informed, data driven decisions regarding patient treatment and safety, study direction and regulatory reporting. ICONIK Patient Safety eliminates the lengthy, manual review of individual patient files, allowing a faster and easier review of aggregated safety events across study populations.
Commenting on the new service, Dr. Peter Schueler, Senior Vice President Medical & Safety Services, ICON Clinical Research, said: “Patient wellbeing is paramount in any clinical trial. ICONIK Patient Safety allows real-time review of integrated patient safety data, thereby improving our ability to identify and monitor unexpected adverse events. ICONIK Patient Safety helps study teams maintain a view of a drug’s evolving safety profile by accumulating safety data in real-time and allowing for quick identification of emerging safety issues, affording greater protection of patients’ well-being. Before ICONIK Patient Safety, this level of dynamic analysis and management of patient safety was simply not possible.”
ICONIK Patient Safety is the latest service to leverage the ICONIK technology platform and follows ICON’s recent announcement of ICONIK Monitoring, a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources.
The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in Forms 20-F for the fiscal year ended December 31st 2012 and in the other forms filed with the US Securities and Exchange Commission, including the F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.